S&P 500   4,238.25 (-1.17%)
DOW   33,108.82 (-0.97%)
QQQ   356.34 (-1.36%)
AAPL   171.21 (-1.46%)
MSFT   316.04 (-1.79%)
META   302.12 (-1.53%)
GOOGL   132.72 (-1.08%)
AMZN   125.94 (-2.72%)
TSLA   247.94 (-1.45%)
NVDA   444.31 (-0.78%)
NIO   8.65 (-1.59%)
BABA   84.29 (-2.59%)
AMD   102.15 (-1.08%)
T   14.74 (+0.48%)
F   12.12 (-1.54%)
MU   68.39 (+0.63%)
CGC   0.70 (-5.56%)
GE   108.53 (-0.24%)
DIS   80.62 (-1.29%)
AMC   7.97 (-2.21%)
PFE   33.86 (-0.24%)
PYPL   57.80 (-1.30%)
NFLX   381.52 (+0.31%)
S&P 500   4,238.25 (-1.17%)
DOW   33,108.82 (-0.97%)
QQQ   356.34 (-1.36%)
AAPL   171.21 (-1.46%)
MSFT   316.04 (-1.79%)
META   302.12 (-1.53%)
GOOGL   132.72 (-1.08%)
AMZN   125.94 (-2.72%)
TSLA   247.94 (-1.45%)
NVDA   444.31 (-0.78%)
NIO   8.65 (-1.59%)
BABA   84.29 (-2.59%)
AMD   102.15 (-1.08%)
T   14.74 (+0.48%)
F   12.12 (-1.54%)
MU   68.39 (+0.63%)
CGC   0.70 (-5.56%)
GE   108.53 (-0.24%)
DIS   80.62 (-1.29%)
AMC   7.97 (-2.21%)
PFE   33.86 (-0.24%)
PYPL   57.80 (-1.30%)
NFLX   381.52 (+0.31%)
S&P 500   4,238.25 (-1.17%)
DOW   33,108.82 (-0.97%)
QQQ   356.34 (-1.36%)
AAPL   171.21 (-1.46%)
MSFT   316.04 (-1.79%)
META   302.12 (-1.53%)
GOOGL   132.72 (-1.08%)
AMZN   125.94 (-2.72%)
TSLA   247.94 (-1.45%)
NVDA   444.31 (-0.78%)
NIO   8.65 (-1.59%)
BABA   84.29 (-2.59%)
AMD   102.15 (-1.08%)
T   14.74 (+0.48%)
F   12.12 (-1.54%)
MU   68.39 (+0.63%)
CGC   0.70 (-5.56%)
GE   108.53 (-0.24%)
DIS   80.62 (-1.29%)
AMC   7.97 (-2.21%)
PFE   33.86 (-0.24%)
PYPL   57.80 (-1.30%)
NFLX   381.52 (+0.31%)
S&P 500   4,238.25 (-1.17%)
DOW   33,108.82 (-0.97%)
QQQ   356.34 (-1.36%)
AAPL   171.21 (-1.46%)
MSFT   316.04 (-1.79%)
META   302.12 (-1.53%)
GOOGL   132.72 (-1.08%)
AMZN   125.94 (-2.72%)
TSLA   247.94 (-1.45%)
NVDA   444.31 (-0.78%)
NIO   8.65 (-1.59%)
BABA   84.29 (-2.59%)
AMD   102.15 (-1.08%)
T   14.74 (+0.48%)
F   12.12 (-1.54%)
MU   68.39 (+0.63%)
CGC   0.70 (-5.56%)
GE   108.53 (-0.24%)
DIS   80.62 (-1.29%)
AMC   7.97 (-2.21%)
PFE   33.86 (-0.24%)
PYPL   57.80 (-1.30%)
NFLX   381.52 (+0.31%)
OTCMKTS:CLXPF

Cybin (CLXPF) Stock Forecast, Price & News

$0.57
+0.04 (+7.55%)
(As of 10/2/2023 ET)
Compare
Today's Range
$0.52
▼
$0.60
50-Day Range
$0.30
▼
$0.63
52-Week Range
$0.49
▼
$3.38
Volume
5.72 million shs
Average Volume
551,962 shs
Market Capitalization
$84.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesShort Interest

CLXPF stock logo

About Cybin (OTCMKTS:CLXPF) Stock

Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.

CLXPF Price History

CLXPF Stock News Headlines

September 14, 2023 | finance.yahoo.com
Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs
January 16, 2023 | benzinga.com
Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
October 6, 2022 | businesswire.com
Cybin Provides Update on its Intellectual Property Portfolio - Business Wire
October 4, 2022 | benzinga.com
Cybin, GH Research Among Top Psychedelic Movers Of Today - Numinus Wellness (OTC:NUMIF), Compass Pathways - Benzinga
September 29, 2022 | proactiveinvestors.com
Mindset Pharma says licensing agreement with Cybin gives it multiple 'shots for the goal' - Proactive Investors USA
September 27, 2022 | benzinga.com
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
September 27, 2022 | proactiveinvestors.com
NA Proactive news snapshot: Nevada Copper, Mindset Pharma, EverGen Infrastructure, Psyched Wellness, BetterLife Pharma, Endexx, Group Eleven Resources... - Proactive Investors USA
October 3, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 21, 2022 | businesswire.com
Cybin to Participate in Upcoming Scientific and Investor Conferences - Business Wire
September 21, 2022 | streetinsider.com
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks 'Tremendous' Milestone as First Participants Receive Initial CYB003 Dose - StreetInsider.com
September 20, 2022 | businesswire.com
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines - Business Wire
September 9, 2022 | bloomberg.com
First Africa Cannabis SPAC to Go Ahead With Cilo Cybin Listing - Bloomberg
September 7, 2022 | benzinga.com
COMP SERVICES (CMPS), (CSE:OPTI) – Psychedelics May Make People Less Afraid of Death - Benzinga
September 1, 2022 | nasdaq.com
7 Psychedelics Stocks to Buy for a Big Drug Boom - Nasdaq
September 1, 2022 | proactiveinvestors.com
Cybin makes positive progress towards its goal of advancing psychedelics to therapeutics - Proactive Investors USA
August 31, 2022 | benzinga.com
(ALID), ATA (ATAI), (BMNDF), COMP SERVICES (CMPS), Cybin Inc. Common Shares (CYBN), Small Pharma (DMTTF), - Benzinga
August 31, 2022 | benzinga.com
Cybin Inc. Common Shares (CYBN) – Cybin Announces Final Adelia Milestone Achievement - Benzinga
August 31, 2022 | businesswire.com
Cybin Announces Final Adelia Milestone Achievement - Business Wire
August 30, 2022 | finance.yahoo.com
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Yahoo Finance
August 30, 2022 | businesswire.com
Wellbeing' CEO Joins Benzinga's Psychedelic Advisory Board - Business Wire
August 30, 2022 | streetinsider.com
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD - StreetInsider.com
August 30, 2022 | businesswire.com
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Business Wire
August 26, 2022 | streetinsider.com
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector - StreetInsider.com
August 24, 2022 | proactiveinvestors.com
Stifel analysts still bullish on psychedelic stocks, citing attractive risk-reward profile - Proactive Investors USA
August 17, 2022 | benzinga.com
MDD - Latest News and breaking headlines - Benzinga
August 17, 2022 | marketscreener.com
Cybin, Clinilabs Says DEA Grants it Schedule 1 License for CYB003 to Treat Major Depressive Disorder - Marketscreener.com
See More Headlines
Receive CLXPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Holding & Other Investment Offices
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CLXPF
CUSIP
N/A
CIK
N/A
Web
www.cybin.com
Phone
416 567 4675
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.57
Quick Ratio
13.57

Sales & Book Value

Annual Sales
$680,000.00
Price / Sales
124.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.44 per share
Price / Book
1.30

Miscellaneous

Outstanding Shares
148,598,000
Free Float
N/A
Market Cap
$84.70 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Eric So L.L.B. (Age 45)
    LLB, Co-Founder, Pres & Exec. Chairman
  • Mr. Douglas L. Drysdale (Age 51)
    Chief Exec. Officer
  • Mr. Paul Glavine (Age 31)
    Co-Founder, Chief Growth Officer & Director
  • Mr. John Kanakis (Age 40)
    Co-Founder & Chief Bus. Officer
  • Mr. Greg Cavers (Age 50)
    Chief Financial Officer
  • Dr. Alex L. Nivorozhkin Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Gabriel Fahel (Age 45)
    Chief Legal Officer
  • Sara Brittany Somerset
    Chief Communications Officers
  • Lori Challenger
    Chief of Staff
  • James Andrews
    Chief Cultivation & Extraction Officer

Key Competitors

View All Competitors













CLXPF Stock - Frequently Asked Questions

How have CLXPF shares performed in 2023?

Cybin's stock was trading at $0.2971 at the beginning of the year. Since then, CLXPF stock has increased by 91.9% and is now trading at $0.57.
View the best growth stocks for 2023 here.

What is Cybin's stock symbol?

Cybin trades on the OTCMKTS under the ticker symbol "CLXPF."

How do I buy shares of Cybin?

Shares of CLXPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cybin's stock price today?

One share of CLXPF stock can currently be purchased for approximately $0.57.

How much money does Cybin make?

Cybin (OTCMKTS:CLXPF) has a market capitalization of $84.70 million and generates $680,000.00 in revenue each year. The company earns $-24,420,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How can I contact Cybin?

The official website for the company is www.cybin.com. The company can be reached via phone at 416 567 4675 or via email at ir@cybin.com.

This page (OTCMKTS:CLXPF) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -